Viatris (VTRS) Stock Overview

Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. More details

VTRS fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	0/6
Financial Health	4/6
Dividends	2/6

Rewards

Trading at 74.6% below our estimate of its fair value

Earnings are forecast to grow 94.1% per year

Trading at good value compared to peers and industry

Risk Analysis

Dividend of 3.3% is not well covered by earnings

VTRS Community Fair Values

Create Narrative

See what 73 others think this stock is worth. Follow their fair value or set your own to get alerts.

Viatris

AnalystHighTarget

Community Contributor

Emerging Markets And Global Aging Will Elevate Biosimilars

Key Takeaways Rapid advancement of innovative products and biosimilars, coupled with unrivaled emerging-market presence, is set to boost growth and diversify earnings streams. Deep integration, cost-saving initiatives, and strategic asset moves could unlock greater structural efficiencies, supporting sustained high profitability and cash flow.

View narrative

US$16

9.2% undervalued

Viatris

Adje1959

Community Contributor

The Viatris (VTRS) Story

The Viatris (VTRS) Story — with Bull‑Scenario Price Target Viatris was created in 2020 through the merger of Mylan and Upjohn, Pfizer’s division of older, off‑patent medicines. Overnight, it became one of the largest global players in generic drugs and biosimilars, operating in more than 165 countries.

View narrative

US$39.24

63.0% undervalued

Viatris

AnalystConsensusTarget

Based on Analyst Price Targets

VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth

Key Takeaways Expansion into emerging markets and innovative product launches support broad revenue growth and decrease dependency on slower-growing regions. Focus on higher-margin products, efficiency measures, and strategic acquisitions enhances profitability and provides a stable platform for long-term earnings.

View narrative

US$14.11

3.0% overvalued

447

Viatris

AnalystLowTarget

Community Contributor

Regulatory Burdens Will Squeeze Margins Though Pipeline Will Offer Little

Key Takeaways Sustained pricing and regulatory pressures are likely to compress margins and increase operating costs across Viatris' core generics business. Heavy debt load and reliance on mature products limit flexibility for growth investments and heighten risks to revenue stability and cash flow.

View narrative

US$8

81.6% overvalued

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

US$21.53

68.3% undervalued

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Viatris Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Viatris
Historical stock prices
Current Share Price	US$14.53
52 Week High	US$16.47
52 Week Low	US$6.85
Beta	0.80
1 Month Change	6.21%
3 Month Change	32.94%
1 Year Change	52.79%
3 Year Change	43.44%
5 Year Change	3.05%
Change since IPO	2,269.66%

Recent updates

Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation

Feb 20

New Product Launches And Expense Savings Will Strengthen Future Operations

Apr 22 New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.

Viatris: One Swallow Doesn't Make A Summer

Feb 27

Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out

Jan 24

Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes

Jan 06

Bargain Priced Viatris Reports Strong Q3 Earnings Results

Nov 08

Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy

Oct 22

Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope

Jun 13

Shareholder Returns

	VTRS	US Pharmaceuticals	US Market
7D	-4.7%	-3.0%	-1.2%
1Y	52.8%	18.9%	19.2%

Return vs Industry: VTRS exceeded the US Pharmaceuticals industry which returned 21% over the past year.

Return vs Market: VTRS exceeded the US Market which returned 17.6% over the past year.

Price Volatility

Is VTRS's price volatile compared to industry and market?
VTRS volatility
VTRS Average Weekly Movement	4.8%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	6.7%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.2%

Stable Share Price: VTRS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: VTRS's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1961	30,000	Scott Smith	www.viatris.com

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.

Viatris Inc. Fundamentals Summary

How do Viatris's earnings and revenue compare to its market cap?
VTRS fundamental statistics
Market cap	US$16.94b
Earnings (TTM)	-US$3.51b
Revenue (TTM)	US$14.30b

1.2x

P/S Ratio

-4.8x

P/E Ratio

Is VTRS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VTRS income statement (TTM)
Revenue	US$14.30b
Cost of Revenue	US$8.64b
Gross Profit	US$5.66b
Other Expenses	US$9.17b
Earnings	-US$3.51b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-3.05
Gross Margin	39.55%
Net Profit Margin	-24.58%
Debt/Equity Ratio	98.0%

How did VTRS perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

-16%

Payout Ratio

Does VTRS pay a reliable dividends?

See VTRS dividend history and benchmarks

When do you need to buy VTRS by to receive an upcoming dividend?
Viatris dividend dates
Ex Dividend Date	Mar 09 2026
Dividend Pay Date	Mar 18 2026
Days until Ex dividend	2 days
Days until Dividend pay date	11 days

Does VTRS pay a reliable dividends?

See VTRS dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/05 13:24
End of Day Share Price	2026/03/05 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viatris Inc. is covered by 31 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Glen Santangelo	Barclays
Aaron Gal	Bernstein

Viatris (VTRS) Stock Overview

Rewards

Risk Analysis

Emerging Markets And Global Aging Will Elevate Biosimilars

The Viatris (VTRS) Story

VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth

Regulatory Burdens Will Squeeze Margins Though Pipeline Will Offer Little

Looking to be second time lucky with a game-changing new product

Viatris Inc. Competitors

Elanco Animal Health

Royalty Pharma

Jazz Pharmaceuticals

Teva Pharmaceutical Industries

Price History & Performance

Recent News & Updates

Price target increased by 9.1% to US$15.39

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2026

FDA Accepts Viatris Inc. Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation

Recent updates

Price target increased by 9.1% to US$15.39

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2026

FDA Accepts Viatris Inc. Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation

Price target increased by 7.6% to US$14.11

Price target increased by 8.7% to US$13.89

Viatris Inc. to Report Q4, 2025 Results on Feb 26, 2026

Viatris Inc. Announces Chief Legal Officer Changes

Biocon Limited (NSEI:BIOCON) completed the acquisition of 8.5% stake in Biocon Biologics Limited from Activ Pine LLP, Serum Institute Life Sciences Pvt. Ltd., Tata Capital Growth Fund II LP, managed by Tata Capital Private Equity, Viatris Inc. (NasdaqGS:VTRS).

Viatris Inc. Announces the Launch of Inpefa

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Viatris Inc. Provides Pipeline Update on Four Regulatory Milestones

Viatris Inc. Appoints David Simmons to Compensation Committee and Science and Technology Committee, Effective December 5, 2025

Upcoming dividend of US$0.12 per share

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Viatris Inc. Raises Financial Guidance for the Year 2025

Second quarter dividend of US$0.12 announced

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2025

Viatris Inc., Annual General Meeting, Dec 05, 2025

Viatris Inc. (NasdaqGS:VTRS) acquired Aculys Pharma, Inc.

Viatris Inc. to Report Q3, 2025 Results on Nov 06, 2025

Viatris Inc.(NasdaqGS:VTRS) dropped from FTSE All-World Index (USD)

Viatris Inc. Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S

Second quarter dividend of US$0.12 announced

Viatris Inc. Reaffirms Earnings Guidance for the Fiscal Year 2025

Viatris Inc. Announces Appointment of David Simmons to the Company's Board of Directors

Viatris Inc. Provides Update on Phase 3 Study of MR-139 for Blepharitis

Viatris Inc. Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Viatris Inc. to Report Q2, 2025 Results on Aug 07, 2025

Viatris Inc. Announces Positive Top-Line Results from Phase 3 Lynx-2 Trial of Mr-142 in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Viatris Inc. Announces Launch of First Clozapine Orally Disintegrating Tablet in Canada

CEO & Director recently bought US$536k worth of stock

CEO & Director recently bought US$536k worth of stock

First quarter dividend of US$0.12 announced

First quarter 2025 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to US$0.076 loss

Viatris Inc. Reaffirms Earnings Guidance for the Fiscal Year 2025

Viatris Inc. Announces Quarterly Dividend, Payable on June 16, 2025

Viatris Inc. Announces Board and Committee Changes

New Product Launches And Expense Savings Will Strengthen Future Operations

Viatris Inc. Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of Effexor®? for the Treatment of Generalized Anxiety Disorder

Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer

Consensus EPS estimates fall by 153%

Shareholder Files A Class Action on Behalf of Purchasers of Viatris Inc

Viatris Inc. to Report Q1, 2025 Results on May 08, 2025

Nussbaum Law Group, P.C. and Roberts Law Firm US, PC Announce a $73.5 Million Class Action Settlement with Mylan on Behalf of Direct Purchasers of EpiPen® or Generic EpiPen

Director exercised options and sold US$3.9m worth of stock

Price target decreased by 9.0% to US$12.01

Fourth quarter dividend of US$0.12 announced

Full year 2024 earnings: EPS misses analyst expectations

Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2025

Viatris: One Swallow Doesn't Make A Summer

Viatris Inc. to Report Q4, 2024 Results on Feb 27, 2025

Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out

FeganScott Announces Class-Action Lawsuit Against Pfizer and Viatris

Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes

Viatris Inc. Announces Publication of Phase 2B Care Study Data for Cenerimod in Lancet Rheumatology